February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of additional years of healthy life globally. Some examples of disease areas in which ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotech firm focused on developing cancer and obesity treatments currently valued at $2.76 million, has announced the expansion of its intellectual ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...

Finding a clinical trial that is a good fit can be challenging. Here's how to get the most out of your clinical trial search.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Swedish biotech company Gesynta Pharma AB has secured $27million in a Series B financing round led by Innovestor Life Science in Finland.